title: Molecular determinants of inverse agonist activity of biologicals targeting CTLA-4.
abstract: Ligation of CD28 or CTLA-4 with some biologicals can activate T cells due to an unexpected superagonist or inverse agonist activity, respectively. The risk of such an outcome limits the therapeutic development of these reagents. Thus, identifying the molecular determinants of superagonist/inverse agonist properties for biologicals targeting costimulatory/inhibitory receptors has not only fundamental value but also important therapeutic implications. In this study, we show that ligation of CTLA-4 with either soluble B7.1 Ig (but not B7.2 Ig) or with a recombinant bispecific in-tandem single chain Fv known as 24:26 induces TCR-independent, T cell activation. Such an inverse agonist activity requires CD28 expression and high CTLA-4 expression and is not seen when CTLA-4 is ligated by membrane-bound B7.1 or B7.2. At the molecular level, the inverse agonist activity of B7.1 Ig or 24:26 correlates with their ability to induce the formation of unique dimer-based, CTLA-4 oligomers on the T cell surface and involves CTLA-4 signaling through its cytoplasmic domain. Our results provide a potential mechanism to explain and to predict inverse agonist activity for CTLA-4 ligands.
authors.affiliation: FOCIS Centre for Clinical Immunology and Immunotherapeutics, Robarts Research Institute, London, Ontario, Canada.
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Teft
authors.forename: Joaquín
authors.initials: J
authors.lastname: Madrenas
mesh_terms: D018033:Antibodies, Bispecific / Q000502:physiology; D015703:Antigens, CD / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D000943:Antigens, Differentiation / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D018122:B7-1 Antigen / Q000276:immunology / Q000378:metabolism; D060908:CTLA-4 Antigen; D003593:Cytoplasm / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D019281:Dimerization; D004318:Doxycycline / Q000494:pharmacology; D016503:Drug Delivery Systems; D006131:Growth Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D019169:Jurkat Cells; D008024:Ligands; D008213:Lymphocyte Activation / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D017384:Sequence Deletion; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*